Market Overview - The main indices showed slight fluctuations today, with the Shanghai Composite Index increasing by 0.13%, the Shenzhen Component Index rising by 0.38%, and the ChiNext Index up by 1.27% [1] - Among the Shenwan first-level industry performances, the sectors of communication, electronics, and media led the gains, while non-ferrous metals, coal, and steel lagged behind [1] Concept Sector Performance - Overall, the Xinjiang revitalization, CRO, and circuit board concepts performed relatively well, while lithium mining, lithium iron phosphate batteries, and rare metals concepts showed weaker performance [1]

Market Overview - The A-share market showed a positive trend today, with major indices mostly rising. The Shanghai Composite Index increased by 0.46% to close at 3875.53 points, while the Shenzhen Component rose by 1.05% to 12828.95 points. The Sci-Tech 50 index gained 1.18% to reach 1357.15 points, and the ChiNext Index surged by 2.29% to 2956.37 points. Overall, 3206 stocks rose, 2085 fell, and 133 remained unchanged, with a total trading volume of 27.5 billion yuan, a decrease of 483.37 million yuan from the previous trading day [1][2]. Industry Performance - Among the primary industries, telecommunications, comprehensive services, non-ferrous metals, pharmaceutical biology, electronics, and machinery equipment led the gains. Conversely, non-bank financials, banking, household appliances, transportation, automotive, and defense industries experienced declines [1][2]. Sector Highlights - The top-performing concept sectors today included optical modules (CPO), gold and jewelry, optical chips, cobalt mines, advanced packaging, CRO, innovative drugs, optical communications, the SMIC industrial chain, generic drugs, weight loss drugs, high turnover, selected rare metals, germanium-gallium-antimony ink, and semiconductor equipment [2].

Market Overview - The A-share market saw most major indices closing higher today, with the Shanghai Composite Index rising by 0.37% to close at 3857.93 points, the Shenzhen Component Index increasing by 0.99% to 12696.15 points, and the ChiNext Index up by 2.23% to 2890.13 points. However, the Sci-Tech 50 Index fell by 1.71% to 1341.31 points [1][14]. - Overall, there were 1997 stocks that rose and 3305 stocks that fell, with 121 stocks remaining flat. The total trading volume in the Shanghai and Shenzhen markets was 27983 billion yuan, a decrease of 1725 billion yuan compared to the previous trading day [1]. Industry Performance - Among the Shenwan first-level industries, the leading sectors included Comprehensive, Power Equipment, Nonferrous Metals, Food & Beverage, and Pharmaceutical & Biological industries, with respective gains of 3.86%, 3.12%, 2.44%, 2.42%, and 1.42%. Conversely, the sectors that experienced declines included Household Appliances, Transportation, Computer, Communication, and Banking, with losses of 1.82%, 1.69%, 1.48%, 0.80%, and 0.76% respectively [1][14]. Concept Sector Performance - The top-performing concept sectors today included Continuous Board, Rare Earth, Power Battery, Rare Metals, CRO, Lithium Battery, Lithium Iron Phosphate Battery, Lithium Electrolyte, Baijiu, Insurance, Small Metals, New Energy Vehicles, and Beverage Manufacturing [2][11].

Group 1 - The stock price of Jinkai Biotechnology is reported at 42.65 yuan, down 1.15 yuan or 2.63% from the previous trading day, with a trading volume of 3.01 billion yuan and a turnover rate of 12.27% [1] - Jinkai Biotechnology is a global small molecule CDMO service provider focused on custom R&D production services for innovative drug manufacturers, covering process development, optimization, and large-scale production [1] - The company operates in sectors including bioproducts, CRO, and weight loss drugs [1] Group 2 - The semi-annual report disclosed on August 23 shows that the company achieved revenue of 348 million yuan in the first half of the year, a year-on-year increase of 32.98% [1] - The net profit attributable to the parent company reached 71.76 million yuan, representing a year-on-year growth of 123.61% [1] - The net profit excluding non-recurring gains and losses was 59.17 million yuan, up 141.51% year-on-year, with a net cash flow from operating activities of 74.72 million yuan, an increase of 14.47% [1] Group 3 - Today, the net outflow of main funds was 19.71 million yuan, accounting for 0.81% of the circulating market value; over the past five days, the cumulative net outflow of main funds was 709,500 yuan, representing 0.03% of the circulating market value [1]

Market Impact - CRO (未明确公司，需根据上下文补充) 的关注度在 Trump Media 合作声明发布后大幅跃升 853% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 承董事會命 北京昭衍新藥研究中心股份有限公司 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 附件為本公司於上海證券交易所網站刊登之 北京昭衍新藥研究中心股份有限公司 (1) 關於召開2025年半年度業績說明會的公告 (2) 2025年半年度報告 (3) 2025年半年度報告摘要 馮宇霞 董事長 中 國 北 京，2025年8月26日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating a strong performance relative to the benchmark index [14]. Core Insights - The company shows a trend of accelerating performance with significant growth in both revenue and profit, supported by a robust order backlog [2]. - Emerging business segments are performing exceptionally well, contributing to overall revenue growth [5][6]. - The traditional small molecule CDMO business remains stable and profitable, with a solid project pipeline [3]. Summary by Sections Financial Performance - In H1 2025, the company achieved revenue of 3.188 billion yuan, a year-on-year increase of 18.20%, and a net profit of 617 million yuan, up 23.71% [1]. - For Q2 2025, revenue reached 1.647 billion yuan, reflecting a 26.94% year-on-year growth, while net profit increased by 33.94% to 291 million yuan [1]. Business Segments - The small molecule CDMO solutions generated revenue of 2.429 billion yuan in H1 2025, a 10.64% increase, accounting for 76.19% of total revenue [2]. - Emerging businesses reported revenue of 756 million yuan, a significant growth of 51.22%, making up 23.71% of total revenue [2]. Market Analysis - Domestic market revenue was 713 million yuan, growing 3.44%, while international market revenue reached 2.475 billion yuan, up 23.27% [2]. - Notably, revenue from European clients surged over 200%, indicating strong demand in that region [2]. Future Projections - The company anticipates continued growth in revenue and profit, with projected revenues of 6.71 billion yuan, 7.686 billion yuan, and 8.727 billion yuan for 2025, 2026, and 2027 respectively [8]. - The expected net profits for the same years are 1.108 billion yuan, 1.294 billion yuan, and 1.516 billion yuan [8].

Financial Overview - Revenue for H1 2025 reached 3,188 million RMB, an increase from 2,697 million RMB in H1 2024 [80] - Adjusted net profit for H1 2025 was 617 million RMB, up from 499 million RMB in H1 2024 [80] - Gross profit margin improved to 43.5%, up from 42.2% in H1 2024 [64] Performance Highlights - Gross margin increased by 1.3 percentage points to 43.5% [13] - Net profit growth outpaced revenue growth by 5.5 percentage points [14] - The company reported a backlog of orders worth 10.88 billion USD, with a year-on-year increase of over 40% [13] Segment Performance Small Molecule Business - Revenue for small molecule CDMO business was 24.29 billion RMB, a 10.6% increase year-on-year [20] - Gross margin for small molecule business reached 47.8%, up 0.6 percentage points [32] Emerging Business - Emerging business revenue surged by 51.2% to 7.56 billion RMB [19] - Gross margin for emerging business was 29.8%, an increase of 9.5 percentage points [20] Clinical CRO Business - Revenue for clinical CRO business was 1.39 billion RMB, reflecting a growth of 44.8% [42] - The company supported 13 projects to obtain clinical trial approvals in China [42] Market Expansion - The company added over 150 new CDMO business clients during the reporting period [22] - Revenue from the US market was 1.789 billion RMB, a slight increase of 0.5% year-on-year [25] - Revenue from the European market grew by over 200% to 548 million RMB [25] Future Outlook - The company anticipates a revenue growth of 13% to 15% for the full year of 2025 [77] - Plans to enhance operational efficiency and profitability, aiming for profit growth to exceed revenue growth [77] - Continued focus on expanding capabilities in peptide, oligonucleotide, and conjugated drug segments [77]

Market Overview - The A-share market showed mixed performance today, with the Shanghai Composite Index falling by 0.39% to close at 3868.38 points, while the Shenzhen Component Index rose by 0.26% to 12473.17 points. The ChiNext Index decreased by 0.76% to 2742.13 points, and the Sci-Tech 50 Index dropped by 1.31% to 1270.87 points [1][13]. - Overall, the market saw a near-even split in individual stock performance, with 2802 stocks rising and 2469 stocks declining, while 152 stocks remained unchanged. The total trading volume in the Shanghai and Shenzhen markets was 2679 billion yuan, a decrease of 462.1 billion yuan compared to the previous trading day [1][13]. Industry Performance - Among the Shenwan first-level industries, the leading sectors included Agriculture, Forestry, Animal Husbandry, and Fishery (up 2.62%), Beauty and Personal Care (up 2.04%), Basic Chemicals (up 1.26%), Media (up 1.23%), and Comprehensive (up 1.09%). Conversely, the sectors that experienced declines included Pharmaceutical and Biological (down 1.09%), Non-Bank Financials (down 1.06%), Steel (down 0.98%), National Defense and Military Industry (down 0.93%), and Communication (down 0.79%) [1][13]. Concept Sectors - The concept sectors that performed well today included Continuous Limit Up, High Send Transfer, Chicken Industry, Consumer Electronics OEM, Smart Speakers, First Board, Wireless Charging, Virtual Reality, Pig Industry, Online Gaming, Biological Breeding, Chemical Fiber, ST stocks, Apple, and New Display Technology [1][10]. - On the other hand, the sectors that saw a pullback included Rare Earth, CRO, and Rare Earth Permanent Magnet [1][10].

Core Viewpoint - On August 25, the three major indices opened collectively higher, indicating a positive market sentiment at the start of the trading day [1] Market Performance - The Shanghai Composite Index opened up by 0.59% - The Shenzhen Component Index opened up by 1.03% - The ChiNext Index opened up by 1.41% [1] Sector Performance - Active sectors at the opening included small metals, semiconductors, securities, education, and AI chip concepts - Declining sectors included banks, traditional Chinese medicine, food and beverage, and CRO concepts [1]